Back to Search
Start Over
Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota
- Source :
- Antimicrobial Agents and Chemotherapy; September 2019, Vol. 64 Issue: 1
- Publication Year :
- 2019
-
Abstract
- CRS3123 is a novel small molecule that potently inhibits methionyl-tRNA synthetase of Clostridioides difficile, inhibiting C. difficiletoxin production and spore formation. CRS3123 has been evaluated in a multiple-ascending-dose placebo-controlled phase 1 trial.
Details
- Language :
- English
- ISSN :
- 00664804 and 10986596
- Volume :
- 64
- Issue :
- 1
- Database :
- Supplemental Index
- Journal :
- Antimicrobial Agents and Chemotherapy
- Publication Type :
- Periodical
- Accession number :
- ejs53329458
- Full Text :
- https://doi.org/10.1128/AAC.01395-19